SOUTH SAN FRANCISCO, Calif., July 25 /PRNewswire/ -- Portola Pharmaceuticals, Inc. announced today that Peggy V. Phillips, former Chief Operating Officer at Immunex, Inc., has been appointed to the Company's Board of Directors.
"Peggy's 25 years of experience in the biopharmaceutical industry will be a great asset to Portola, and we are pleased to welcome her to our Board," stated Charles Homcy, M.D., President and CEO of Portola. "In particular, Peggy's insight into shepherding drugs from development through approval and launch will help guide Portola's strategy as we advance our clinical programs through development."
Phillips most recently served as the Chief Operating Officer at Immunex from 1999 until the company was acquired by Amgen in 2002. In this capacity, she was responsible for all development, manufacturing, and sales and marketing activities. Prior to her COO role, Phillips served as the General Manager for Enbrel and was responsible for the company's launch of its flagship product. From 1994 to 1998, Phillips was the Senior Vice President of Pharmaceutical Development for Enbrel, responsible for product development from research to approval. Phillips served on the Immunex Board of Directors from 1996 to 2002 and currently serves on the Board of Directors of the United States Naval Academy Foundation.
About Portola
Portola Pharmaceuticals, Inc. is a private biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. We are conducting a Phase II clinical trial with our oral Factor Xa inhibitor for the prevention of deep vein thrombosis, and a Phase I clinical program with our direct-acting, oral and IV ADP receptor antagonist. These drug candidates could potentially advance patient care in the $14 billion anti-thrombotics market. Portola also has a robust drug discovery platform focusing on the platelet and signaling pathways that mediate thrombosis and inflammation. Portola's investors include Abingworth, Alta Partners, ATV, Frazier Healthcare Ventures, MPM Capital, Prospect Ventures and Sutter Hill Ventures.
Portola Pharmaceuticals, Inc.CONTACT: Carol Olson of Portola Pharmaceuticals, +1-650-246-7300, orpr@portola.com; or Trista Morrison of Porter Novelli Life Sciences,+1-858-527-3490, or tmorrison@pnlifesciences.com, for PortolaPharmaceuticals
Web site: http://www.portola.com/
